Thrilled to share the results of the KAIAK study published today in @TheLancetEndo Islet transplantation is associated with improved patient and kidney graft survival in patients with #T1D and a kidney transplant @francois_pattou 👉 https://t.co/3yqn3Reo8D @francois_pattou
I'm excited to see this true GFR measurement drug/device nearing FDA approval.
Imagine injecting a inert fluoroprobe, slapping a pulse-ox like monitor on them and in less than 1 hr knowing their mGFR. You could also monitor for changes in mGFR over12-24h.
https://t.co/qhyS4e7sN1
Good article to revisit after FLOW trial. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes - American Journal of Kidney Diseases https://t.co/8NQ6NO9kcf @AJKDonline
What is the benefit of diagnosing primary aldosteronism?
Diagnosis and surgical cure improves cardiovascular and overall mortality compared to medically controlling blood pressure.
Surgical treatment (ADX) of an aldosterone producing adrenal adenoma ⬇️ 43% all-cause mortality compared to mineralocorticoid antagonist (MRA) treatment
Source: ENDO 2024 Anand Vaidya, MD
https://t.co/w4iVsDIlqL
In my advanced CKD clinic, this is a common clinical encounter: Mr. Jones is 83 and has chronic kidney failure with a low eGFR. He’s not eligible for a transplant.
If you do more pre-transplant biopsies (@pithia_trial), you find more things. What do they mean for predicting transplant outcome? Latest work from @CUH_Transplant.
https://t.co/XhY7pqLlXs
This is not the fault of the excellent @geekymedics but a lack of vision from senior clinicians, academics, universities and examining bodies to move with the times. Surely it’s time for a change and to teach medicine how it is practised now.
@askrenal#askrenal if a patient with rapid CKD and hypertension has critical renal artery stenosis bilaterally, but one kidney is normal size and the other is atrophic. Do you stent
Hypothetical 50y.o. with diabetic nephropathy (no RAS) losing 5ml/min/yr.
eGFR 46, uACR 400mg/mmol (3500 mg/g), no ‘4 pillar’ meds.
You add max RASi, flozin, nsMRA, GLP1RA.
4 month review - BP good, uACR down >90%. The lowest eGFR you’ll ’tolerate’ without stopping a med is:
The FLOW trial results are live at @nejm as well
#ERA24
https://t.co/C6DGQf6wVK
Primary composite kidney ✅
CV Death✅
All cause death ✅
GFR slope ✅
First MACE ✅
Kidney specific composite ✅